187 related articles for article (PubMed ID: 37504326)
21. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center.
Huang CQ; Yang XJ; Yu Y; Wu HT; Liu Y; Yonemura Y; Li Y
PLoS One; 2014; 9(9):e108509. PubMed ID: 25259574
[TBL] [Abstract][Full Text] [Related]
22. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
23. Surgical Options for Peritoneal Surface Metastases from Digestive Malignancies-A Comprehensive Review.
Eftimie MA; Potlog G; Alexandrescu ST
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837456
[TBL] [Abstract][Full Text] [Related]
24. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
[TBL] [Abstract][Full Text] [Related]
26. A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis.
Arjona-Sanchez A; Esquivel J; Glehen O; Passot G; Turaga KK; Labow D; Rufian-Peña S; Morales R; van der Speeten K
Surg Endosc; 2019 Mar; 33(3):854-860. PubMed ID: 30003349
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis.
Narasimhan V; Tan S; Kong J; Pham T; Michael M; Ramsay R; Warrier S; Heriot A
Colorectal Dis; 2020 Nov; 22(11):1482-1495. PubMed ID: 32027455
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies.
de Cuba EM; Kwakman R; Knol DL; Bonjer HJ; Meijer GA; Te Velde EA
Cancer Treat Rev; 2013 Jun; 39(4):321-7. PubMed ID: 23244778
[TBL] [Abstract][Full Text] [Related]
29. Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry.
Kelly ME; O'Sullivan NJ; Bolger JC; Polignano F; Youssef H; Renehan A; Malcomson L; Alves S; Cecil T; Mulsow J; Moran B; Mohamed F;
Br J Cancer; 2023 Jan; 128(1):42-47. PubMed ID: 36347966
[TBL] [Abstract][Full Text] [Related]
30. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
31. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia.
Wang TY; Chen CY; Lu CH; Chen MC; Lee LW; Huang TH; Hsieh MC; Chen CJ; Yu CM; Chuang HC; Liao TT; Tseng CW; Huang WS
Int J Hyperthermia; 2018 May; 34(3):328-335. PubMed ID: 28562119
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.
Hallam S; Tyler R; Price M; Beggs A; Youssef H
BJS Open; 2019 Oct; 3(5):585-594. PubMed ID: 31592510
[TBL] [Abstract][Full Text] [Related]
34. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
35. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience.
Valenzuela CD; Levine EA; Mangieri CW; Gawdi R; Moaven O; Russell G; Lundy ME; Perry KC; Votanopoulos KI; Shen P
Ann Surg Oncol; 2022 Jun; 29(6):3436-3445. PubMed ID: 35286531
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
[TBL] [Abstract][Full Text] [Related]
37. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
[TBL] [Abstract][Full Text] [Related]
38. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.
Yang XJ; Huang CQ; Suo T; Mei LJ; Yang GL; Cheng FL; Zhou YF; Xiong B; Yonemura Y; Li Y
Ann Surg Oncol; 2011 Jun; 18(6):1575-81. PubMed ID: 21431408
[TBL] [Abstract][Full Text] [Related]
39. [Surgical Management of Peritoneal Surface Malignancy with Respect to Tumour Type, Tumour Stage and Individual Tumour Biology].
Beckert S; Struller F; Grischke EM; Glatzle J; Zieker D; Königsrainer A; Königsrainer I
Zentralbl Chir; 2016 Aug; 141(4):415-20. PubMed ID: 24241953
[TBL] [Abstract][Full Text] [Related]
40. Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy.
Kleber J; Yang Zhou J; Weber F; Bitterer F; Hauer P; Kupke P; Kronenberg K; Geissler EK; Schlitt HJ; Hornung M; Hutchinson JA; Werner JM
Cancer Immunol Immunother; 2023 Nov; 72(11):3867-3873. PubMed ID: 37580610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
